Anzeige
Mehr »
Login
Dienstag, 24.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14NHV | ISIN: BE0974280126 | Ticker-Symbol: BT1
Berlin
23.12.24
17:11 Uhr
0,006 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOSENIC SA Chart 1 Jahr
5-Tage-Chart
BIOSENIC SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0140,01423.12.

Aktuelle News zur BIOSENIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.12.XFRA BT1: AUSSETZUNG/SUSPENSION121DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOSENIC S.A. BT1...
► Artikel lesen
28.10.BioSenic provides third quarter 2024 Business Update339BioSenic provides third quarter 2024 Business Update BioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024...
► Artikel lesen
07.10.BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.15
30.09.BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors184PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme...
► Artikel lesen
30.09.BioSenic reports half year 2024 results490REGULATED INFORMATIONThe interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated...
► Artikel lesen
BIOSENIC Aktie jetzt für 0€ handeln
17.09.Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO459PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, September 17, 2024 7.00pm CEST - BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and...
► Artikel lesen
19.08.BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.1
14.08.BioSenic: Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis133INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes, including...
► Artikel lesen
13.08.Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform1
13.08.BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.1
19.07.BioSenic S.A.: Transparency notification received from Mr François Rieger1
18.07.BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD162Press Release The upcoming Phase 3 trial with ATO is more robust following a new post-hoc analysis. Mont-Saint-Guibert, Belgium, July 18, 2024, 7.00 am CEST - BIOSENIC (Euronext Brussels and Paris:...
► Artikel lesen
12.07.BioSenic S.A.: Transparency notification received from Véronique Pomi2
05.07.BioSenic to extend US patent for ATO use in sepsis treatment1
05.07.Medsenic, subsidiary of BioSenic SA, extends key patent to the United States1
02.07.Medsenic, BioSenic's subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.2
28.06.BioSenic S.A.: Information on the total number of voting rights and shares1
14.06.The Enterprise Court of Nivelles approves the BioSenic restructuring plan215PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST - BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune...
► Artikel lesen
06.06.BioSenic announces 2023 full year results252PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023. BioSenic has prepared a global restructuring plan covering the years 2024-2032...
► Artikel lesen
28.05.XFRA BT1: WIEDERAUFNAHME/RESUMPTION194FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2